astrazeneca glp-1 The Rise of the GLP-1s: Beyond Diabetes and Obesity AstraZeneca obesity pill helps patients

Slower gut motility can increase susceptibility to conditions like SIBO, IMO, or ISO in some people, while others may tolerate GLP-1 therapy with minimal gastrointestinal impact

In addition, long-term use of GLP-1RAs may also have potential safety risks, such as pancreatitis (Shetty et al., 2022) and thyroid diseases (Bezin et al., 2023), which require continuous monitoring and evaluation

Studies suggereren dat 25 tot 40 procent van het verloren gewicht bestaat uit vetvrije massa, waaronder spieren

Over time, reduced appetite may also lead to lower intake of protein and key nutrients if the diet is not managed intentionally

Cagrilintide incorporates structural modifications that extend its half-life and prolong receptor interaction